Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

NetScientific provides more backing for cancer immunotherapies developer

The transatlantic healthcare IP commercialisation group has upped its stake in PDS Biotechnology
Stop prostate cancer
PDS's cancer treatment pipeline includes compounds for prostate, ovarian, breast and colorectal cancers

NetScientific PLC (LON:NSCI) has upped its stake in PDS Biotechnology, a developer of cancer immunotherapies and vaccines for infectious diseases.

The Aim-listed firm exercised warrants for 1.39mln shares at a cost of US$687,493.

NetScientific has now invested a total of US$3.5ln in PDS Biotechnology, giving it a 14.6% stake.

PDS is operating in the exciting area of immuno-oncology – activating the body's own immune system to recognise and destroy cancer cells.

The field has caused a lot of excitement in the medical world, but one of the major drawbacks has been reports of debilitating toxicities – a drawback PDS has conquered with its Versamune T-cell (a type of white blood cell) activating platform.

PDS's cancer treatment pipeline includes compounds for prostate, ovarian, breast and colorectal cancers, in addition to its lead PDS0101 programme for several HPV-related cancers – HPV, or human papillomavirus, being a virus that infects the skin and the cells lining body cavities.

PDS has positive phase I/IIa trial data under its belt and has agreed partnership funding from the National Institute of Health and MD Anderson for three phase II clinical trials.

Shares in NetScientific rose 2.3% to 67p on the news.

John-H.jpg
Why Invest In Netscientific PLC? Read More Here

Register here to be notified of future NSCI Company articles
View full NSCI profile View Profile

Netscientific PLC Timeline

Related Articles

Drugs
May 03 2017
The hybrid pharma services and drug development group has hit some key milestones over this year as trial results are eyed.
Concept of a DNA strand
May 30 2017
Proactive Investors takes a closer look at an AIM-listed biotech firm that is making advances altering the inner workings of the human body to tackle deadly diseases
picture of blood phials
May 11 2017
“2017 is off to a strong start and …we look forward to achieving additional milestones in the second quarter."

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use